Hang Feng Technology Innovation Co., Ltd. Announces First Half 2026 Financial Results

PR Newswire

HONG KONG, Sept. 8, 2026 /PRNewswire/ — Hang Feng Technology Innovation Co., Ltd. (“Hang Feng Technology Innovation” or the “Company”), a Nasdaq-listed company headquartered in Hong Kong, announced its financial results for the six months ended June 30, 2026 (the “Reporting Period”) as previously furnished to the U.S. Securities and Exchange Commission on a current report on Form 6-K on September 4, 2026. The Company continues to execute its long-term strategic transformation while maintaining a highly capitalized and resilient balance sheet.

Key Financial & Operational Highlights

  • Capital Resources & Balance Sheet: As of June 30, 2026, total assets were $8,215,946, including $6,606,369 in cash. Total shareholders’ equity remained at $8,015,004.
  • Financial Performance: Total revenue for the Reporting Period was $362,511 (compared to $1,327,707 in the first half of 2025). The Company reported a net loss of $553,033 and a comprehensive loss of $593,754 (compared to net income of $363,524 and comprehensive income of $330,221 in the first half 2025). The net loss was primarily attributable to a sharp decline in revenue from the management consulting business. The decrease in corporate management consulting services revenue was primarily due to the Company’s shift in its strategic focus, which resulted in a reduction in business development and marketing activities for its existing operations and a reallocation of resources toward the development of its RWA initiatives. In response to these adjustments, the Company has been actively exploring new market opportunities to realign its operations with the evolving environment.
  • Interest Income Cushion: The Company recorded $329,755 in loan interest revenue during the Reporting Period, delivering a source of cash flow as core operations undergo realignment.

Strategic Corporate Development & Operational Updates

  1. Incorporation of Singapore Subsidiary: In May 2026, the Company incorporated a wholly‑owned subsidiary, HF Helios AI PTE Limited, in Singapore. The subsidiary was established to prepare for prospective cross‑border and tech‑driven business initiatives, and has not yet commenced operations.
  2. Capital Structure Reorganization: Following shareholder approval at the Extraordinary General Meeting on June 12, 2026, the Company completed a share capital re‑designation. The statutory capital structure was reorganized into 9,000,000,000 Class A Ordinary Shares and 1,000,000,000 Class B Ordinary Shares. As of June 30, 2026, 3,871,000 Class A Ordinary Shares and 4,000,000 Class B Ordinary Shares were issued and outstanding.
  3. Regulatory Licenses: Through its Hong Kong subsidiary, Hang Feng International Asset Management Limited (“HF IAM”), the Company held Type 4 (Advising on Securities) and Type 9 (Asset Management) regulated licenses issued by the Securities and Futures Commission (“SFC”) as of June 30, 2026. Subsequent to the Reporting Period, on July 7, 2026, HF IAM was granted a Type 1 (Dealing in Securities) license. The Company continues to advance its license portfolio to support diversified financial offerings.

Executive Commentary

XU Zhiheng, Chief Executive Officer of Hang Feng Technology Innovation, stated:

“The first half of 2026 was a period of proactive strategic reassessment for Hang Feng Technology Innovation. As highlighted in our financial report, our financial results reflect the shift in our strategic focus, leading to a planned reduction in business development and marketing activities for our traditional consulting sector as we reallocate resources toward our long-term RWA initiatives. Backed by a sound balance sheet with over $8 million in total assets and available liquid reserves, we believe we are well‑positioned to navigate near‑term uncertainties while remaining focused on long‑term value creation for our shareholders.”

About Hang Feng Technology Innovation Co., Ltd.

Hang Feng Technology Innovation Co., Ltd. is a Hong Kong‑based company providing comprehensive corporate management consulting solutions alongside specialized asset management services tailored to diverse client needs. Since 2023, Hang Feng has been offering consulting services through Starchain Investment Trading Limited (“Starchain”), one of its wholly‑owned subsidiaries, to a growing network of clients. Starchain delivers tailored management consulting, including strategic growth insights, performance management reporting, key performance indicator (KPI) advisory, and support in regulatory compliance, risk management, and corporate governance practices. In 2024, Hang Feng launched asset management services through its wholly‑owned subsidiaries, introducing structured solutions designed to manage and grow both corporate and individual capital portfolios. For more information, please visit Hang Feng’s IR website: https://ir.hfintech.io.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify many (but not all) of these statements by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue,” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will prove correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Investors are encouraged to review other factors that may affect the Company’s future results in the Company’s registration statement and other filings with the SEC.

Media & Investor Relations Contact

Hang Feng Technology Innovation Co., Ltd.
Email: [email protected]
Website: ir.hfintech.io

Cision View original content:https://www.prnewswire.com/news-releases/hang-feng-technology-innovation-co-ltd-announces-first-half-2026-financial-results-302872026.html

SOURCE Hang Feng Technology Innovation Co., Ltd.

IsoEnergy Completes Summer Drilling at Larocque East, Intersecting Widespread and Strongest Radioactivity to Date Along the Hurricane South Trend

PR Newswire

TORONTO, September 8, 2026 /PRNewswire/ — IsoEnergy Ltd. (“IsoEnergy”, or the “Company”) (NYSE American: ISOU); (TSX: ISO) is pleased to report on radioactive zones intersected in summer drilling along the Hurricane South Trend on the Larocque East project (the “Project“), which hosts the high-grade Hurricane deposit (“Hurricane” or the “Deposit“). Summer drilling at Larocque East totaled 10,159 m in 26 holes, for a year-to-date total of 16,963 m in 43 drill holes (Figure 1). The summer program was expanded from a planned 8,000 m, 20-hole program to follow up on encouraging winter and early summer results (see news release dated July 8, 2026). Highlights of drill core radiometric results and uranium geochemistry from the winter holes were reported on April 7, 2026 and May 12, 2026, respectively. All samples from the summer program have been submitted to SRC Geoanalytical Laboratories and results will be reported when available.

Hurricane hosts a current Mineral Resource of 48.6 Mlb U3O8 at 34.5% U3O8 Indicated, and 2.7 Mlb U3O8 at 2.2% U3O8 Inferred (see “Qualified Person Statement” below). The Project benefits from excellent infrastructure, located approximately 40 km northwest of the McClean Lake mill, and features relatively shallow mineralization at approximately 325 m depth, supporting efficient exploration and future development optionality. The Deposit is located on the Larocque Trend, an important regional structure that also hosts other notable high-grade occurrences including those on Cameco and Orano’s Dawn Lake joint venture.

Highlights

  • The summer drill program successfully intersected widespread, strongly elevated radioactivity over a strike length of 600 m along the South Trend.

    • 18 of the 26 holes returned intervals at or above the cut-off of >350 cps threshold over 0.5 m, 13 holes returned 1,000 cps or greater, and three holes returned over 35,000 cps including the strongest radioactivity drilled to date on the South Trend. All radioactivity results reported herein are measured on drill core as total counts per second (“cps”) with three readings averaged over each 0.5 m sample interval.
  • Drill holes LE26-250 and LE26-273 intersected strongly elevated radioactivity on the L fault zone along strike east and west of mineralization previously reported in winter drill hole LE26-248 (4.21% U

    3

    O

    8

    over 3.5 m, including up to 11.6% U

    3

    O

    8

    over 1.0 m).

    • LE26-250, drilled 75 m east of LE26-248 and outside the existing Hurricane footprint, intersected 11,075 cps over 3.5 m, including 43,160 cps over 0.5 m (see news release dated July 8, 2026).
    • LE26-273, drilled 11 m west of LE26-248, intersected 14,135 cps over 3.0 m, including 36,292 cps over 1.0 m. Like LE26-248, LE6-273 was drilled in the southernmost portion of the Deposit footprint in an area previously interpreted as within the low-grade shell. This interpretation will be revisited once uranium geochemistry results are available.  
  • Drill hole LE26-254 intersected strongly elevated radioactivity, on strike west of previously reported mineralization in winter drill hole LE26-234 (1.00% U

    3

    O

    8

    over 1.5 m, including up to 2.75% U

    3

    O

    8

    over 0.5 m), on the interpreted L fault zone 510 m east of the existing Hurricane footprint.

    • LE26-254, drilled 28 m west of LE26-234, intersected 10,110 cps over 2.0 m, including 35,900 cps over 0.5 m.

Table. 1 Selected Radioactivity Highlights, 2026 Summer Program, Larocque East Project1,2,3,4


Hole ID


Target Area


From (m)


To (m)


Length (m)


Radioactivity (cps)


LE26-250


West L Fault


341.0


344.5


3.5


11,075


Includes


342.0


342.5


0.5


43,160


LE26-254


East L Fault


331.5


333.5


2.0


10,110


Includes


333.0


333.5


0.5


35,900


LE26-273


West L Fault


328.0


331.0


3.0


14,135


Includes


328.5


329.5


1.0


36,292

1. See Table 2 for a listing of individual 0.5 m mineralized intervals defined as intervals over which average RS-125 handheld spectrometer readings on drill core exceeded 350 cps.

2. Radioactivity is total gamma from drill core measured with an RS-125 hand-held spectrometer.

3. Individual 0.5 m interval cps values reported throughout this press release are averages of three readings taken over the 0.5 m interval.

4. Measurements of total gamma cps on drill core are an indication of uranium content but may not correlate with uranium chemical assays.

Dan Brisbin, Vice President Exploration, commented, “Our Larocque project team and contractor partners safely completed an expanded summer program despite a temporary demobilization in June due to a nearby wildfire. Nearly half of the holes drilled in 2026 intersected elevated radioactivity. Multiple holes along the Hurricane South Trend returned strongly elevated results, including thirteen of the twenty-six summer holes at 1,000 cps or greater, both inside the Hurricane deposit footprint and along strike of it. Geochemical results are pending, and those assays, together with the geological observations from drill core, will shape how we define targets for 2027.”

Hurricane Resource Expansion Drilling

Summer drilling focused on expansion of the Hurricane mineral resource. Twenty-six holes were completed to target, with three holes abandoned in sandstone, for a total of 10,159 m. This was expanded from a planned 8,000 m in twenty holes based on early encouraging results. Aside from one hole (LE26-269) that tested the eastern extension of the Hurricane Main trend (Figure 1), all drilling was focused on the Hurricane South Trend. Within the South Trend, six holes tested J and K faults, and seventeen holes tested L fault. LE26-273 tested the L fault within the existing Deposit footprint and extended the zone of elevated radioactivity associated with mineralization intersected by winter hole LE26-248 (4.21% U3O8 over 3.5 m, including up to 11.6% U3O8 over 1.0 m) 11 m to the west.

The Hurricane area geological interpretation is being updated based on information gathered from the forty-three drill holes completed in 2026. Geochemical results will be added when received, and new and existing information integrated during evaluation of 2027 drill target potential.

Figure 1 – Map of the Larocque Trend on the Larocque East project showing the Hurricane deposit, drill hole unconformity intercept locations, and the interpreted traces of the H, I, J, K and L faults at the unconformity. The J, K and L faults, which comprise the Hurricane South Trend, were the focus of summer drilling. 2026 summer drill holes are colour-coded by radioactivity (cps) x core length (m) product (e.g. 1200 cps intersected along a 2 m core interval has a cps.m product of 2400). Previously released geochemical results for winter drill holes (see May 12, 2026 news release) are also shown. Unmineralized winter holes are labelled but not colour-coded for cps. 2025 and earlier drill holes are not labelled. Radiometric results for mineralized intervals in summer 2026 drill holes are provided in Table 2. *See Qualified Person Statement below.

The east-striking structures at Hurricane are grouped into three trends: the North Trend (not shown, minor unnamed faults north of the deposit), Main Trend (H and I faults), and the South Trend (J, K and L faults).

West L Fault Target

LE26-255, LE26-257, LE26-261, LE26-268, and LE26-270 to LE26-274 were drilled to follow up on strong radioactivity intersected in drill holes LE26-248 and LE26-250 on the L-fault zone. A strong illite spectral mineralogy signature dominates through the lower 150 m of sandstone with the lowermost five metres of sandstone dominantly characterized by a mix of illite and chlorite in most holes.

The West L fault target area was a major focus of the summer drill program. Many of the drill holes tested the optimal target position, specifically LE26-250, LE26-261, LE26-268, and LE26-273, where the results correlate with strongly elevated radioactivity. The Company is advancing a geological model for the area to assess its potential based on the winter and summer results.

LE26-250, drilled 75 m east of LE26-248, intersected 11,075 cps over 3.5 m, including 43,160 cps over 0.5 m (see news release dated July 8, 2026). This hole was drilled outside of the existing Hurricane footprint.

LE26-253 intersected elevated radioactivity averaging 620 cps over 0.5 m between 337.5 and 338.0 m, about 3 m above the unconformity (see news release dated July 8, 2026).  The sandstone column is dominantly illitic.

LE26-255 was drilled 30 m east of LE26-250 to test for mineralization The sandstone below 130 m is strongly illitic, transitioning to a mixture of chlorite and illite within 5.0 m of the unconformity. The sandstone is strongly altered with clay and limonite centred on fault zones 70 m above the unconformity. A 0.5 m graphitic fault was intersected 20.0 m below the unconformity.

LE26-257 was completed to test mineralization between LE26-243 and LE22-115A. It intersected an average of 686 cps from 326.5 to 331.0 m, including 1,960 cps and 1,225 cps over 0.5 m intervals. The sandstone column is dominantly illitic below 100 m. Limonite, chlorite, and secondary hematite alteration are associated with the mineralized interval.

LE26-261 intersected 1,094 cps over 3.0 m from 331.0 to 334.0 m. The sandstone column is dominantly illitic starting 215 m above the unconformity.

LE26-268 intersected 1,115 cps over 1.0 m from 329.5 to 330.5 m. The sandstone is dominantly illitic, apart from a 35 m interval in the lower sandstone.

LE26-270 intersected 870 cps over 1.0 m from 327.5 to 328.5 m. The sandstone column is dominantly illitic throughout, with the basal 2.0 m consisting of a mixture of illite, chlorite, and sudoite.

LE26-271 didn’t intersect elevated radioactivity, but significant alteration and structure were intersected starting 100 m above the unconformity. Fault-controlled hydrothermal hematite was intersected at 287 m and 302 m. Spectral clay analysis shows strong illite starting 200 m above the unconformity.

LE26-271C1 intersected 498 cps over 1.0 m from 330.0 to 331.0 m. The sandstone is dominantly illitic with mix of illite and chlorite from 5 m above the unconformity

LE26-272 intersected elevated radioactivity over 3.0 m from 322.5 to 327.0 m, featuring a maximum of 1,893 cps over 0.5 m. Illite dominated sandstone starts 200 m above the unconformity.

LE26-273 intersected elevated radiometry from 328.0 to 331.0 m, averaging 14,135 cps, including 36,292 cps over a 1.0 m interval.

LE26-274 intersected elevated radioactivity from 330.0 to 333.0 m, with a peak reading of 1,190 cps over a 0.5 m interval.

J and K Fault Targets

Drillholes LE26-251, LE26-258, LE26-259, LE26-260, LE26-265B, and LE26-267 targeted interpreted J fault at the unconformity.

LE26-251 was drilled to test the J fault at the unconformity (see news release dated July 8, 2026).  The sandstone column is illitic starting 180 m above the unconformity. The lower sandstone is moderately bleached, with frequent desilicified and argillized intervals centered on structure. Elevated radioactivity up to 1,580 cps was intersected over 0.5 m from 331.5 m to 332.0 m within an interval with strong sooty pyrite alteration, and within a broader interval straddling the unconformity which averages 980 cps over 3.0 m from 331.0 m to 334.0 m. The hole intersected the unconformity 6 m north of optimal target. LE26-258 was drilled to test the K fault at the unconformity. The hole intersected a strongly graphitic and pyritic unit that hosts multiple faults. The unconformity intercept in this hole is interpreted to be 10 metres south of the optimal target.

LE26-259 was drilled to test the K fault at the unconformity. The hole did not intersect elevated radioactivity.  A strongly graphitic fault is present 26 m below unconformity. The drill hole is interpreted to be 4 m north of the optimal target.

LE26-260 was drilled to test J fault at the unconformity. The hole intersected 1,971 cps over 4.5 m from 330.0 to 334.5 m, including 6,430 cps over 0.5 m. The sandstone column is illitic starting 200 m above the unconformity. The lower sandstone is strongly bleached, with frequent desilicified and argillized intervals centred on structure. Basement core includes strongly graphitic intervals and multiple graphitic faults. The hole tested optimal target.

LE26-265B was drilled to test J fault at the unconformity. The hole intersected strong alteration and structure in the basal sandstone and basement; however, no significant radioactivity was intersected. The drill hole is interpreted to 6 m north of the optimal target.

LE26-267 was drilled to test K fault at the unconformity. The hole didn’t intersect significant radioactivity. Moderate bleaching and interstitial clay were intersected through the lower sandstone. The drill hole intersected moderately illitic sandstones from 150 m to 15 m above the unconformity.  The basal 10 m of sandstone is a mix of chlorite and illite.  Basement core hosts multiple graphitic faults and the most significant is a 30 cm graphitic fault, intersected 13 m below the unconformity. The drill hole is interpreted to be 5 m north of the optimal target.

Central L Fault Target

Drill holes LE26-256 and LE26-263 were completed to extend mineralization intersected in LE21-101 and LE25-207. LE26-256 intersected an average of 633 cps over 2 m. A 16 m wide zone of broken core with moderate alteration was intersected 25.8 m above the unconformity, including strong hydrothermal hematite over a 2 m interval at 294 m. Basement core intersected a metre-scale cataclastic fault 39 m below the unconformity. This basement fault was targeted with drill hole LE26-263, which intersected 2,023 cps over 1.0 m from 322.5 to 323.5 m. The middle and basal sandstone is dominantly illitic in both drillholes. A significantly altered fault zone consisting of clay, limonite, and desilicification was intersected 19 m above the unconformity in drill hole LE26-263. Sooty pyrite and chloritization are associated with the mineralized zone, and basement core is strongly chloritized down to 10 m below the unconformity. Potential remains open along east for 150 m.

Hurricane Main Trend Target

LE26-269 was drilled on the Hurricane Main Trend 40 m east of the existing Deposit footprint. It intersected a maximum of 476 cps over a 0.5 m sample. The sandstone column 170 m above the unconformity is strongly illitic, while the basal 5 m above the unconformity contains a mixture of chlorite and kaolinite.

Southeast L Fault Target

Drill holes LE26-252, LE26-254, LE26-262, LE26-264, LE26-266A were completed on the eastern portion of interpreted L-fault. 

LE26-252 was drilled 30 m east of mineralized winter hole LE26-234 (see news release dated July 8, 2026). The sandstone is moderately bleached below 143.5 m. Multiple fault zones with strong quartz dissolution and white clay were intersected through lower sandstone. The basement rocks are moderately to strongly clay altered to 337.7 m, with weakly elevated radioactivity intersected within the clay altered zone (450 cps over 0.5 m from 333.5 m to 334.0 m). The drill hole is interpreted to be 8 m north of the optimal target.

LE26-254 was drilled 27 m west of mineralized drill hole LE26-234. It intersected elevated radioactivity immediately below the unconformity from 331.5 to 333.5 m averaging 10,110 cps, including 35,900 cps over 0.5 m. The lower sandstone unit is strongly altered, with bleaching, argillization, and desilicification centered on fault zones, alongside patches of hydrothermal hematite immediately above the mineralized zone. The sandstone column below 140 m has a dominantly illitic signature. Basement core down to 40 m below the unconformity is moderately altered with pervasive, mineral-controlled clay and chloritization. Radioactivity was intersected in the basement rather than at the unconformity, but the drill hole is interpreted to have tested the optimal target position, with the basement structure intersected immediately below the unconformity.

LE26-262 was drilled up-dip of a basement structure intersected in drill hole LE26-252. It intersected strong alteration consisting of bleaching, desilicification, and argillization roughly 100 m above the unconformity. The basal sandstone includes secondary hematitization centred on a fault and strong clay replacement. The hole is interpreted to have intersected the unconformity 12 m south of the optimal target.

LE26-264 was drilled to test the L fault at the unconformity between LE26-234 and LE26-254. The hole intersected 849 cps over 5.0 m from 324.0 to 329.0 m, including 2,490 cps over 1.0 m from 326.5 to 327.5 m. Middle and basal sandstone is dominantly illitic. Strongly bleached core begins 50 m above the unconformity, featuring patches of limonite and argillized intervals. A secondary radioactive interval in the basement (610 cps at 334.5 m) is associated with secondary hematite and clay. The hole achieved its objective, intersecting elevated radioactivity at the unconformity.

LE26-266A was planned as step-out hole approximately 140 m east of mineralization intersected in previous holes to test the extent of the alteration footprint in the eastern part of the L-fault. It intersected strongly bleached, argillized, and limonitized alteration centred on a fault zone over an 80.0 m wide interval above the unconformity. The unconformity intercept is 20 m south of the interpreted optimal target and potential along strike remains open.

Table 2. Summer 2026 drill hole summary and RS-125 spectrometer results on intervals in which radioactivity exceeded 350 cps averaged over 0.5 m measured on core. 

Table 2 footnote - LE26-265, LE26-265A, and LE26-266 were abandoned in sandstone and not listed. LE26-271C1 is a wedge off LE26-271. Both were completed to target and so both are listed.

Table 2.

Table 2.

Qualified Person Statement

The scientific and technical information contained in this news release was reviewed and approved by Dr. Dan Brisbin, P.Geo., IsoEnergy’s Vice President, Exploration, who is a “Qualified Person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects). See the April 7, 2026 press release for information on quality assurance/quality control procedures. Dr. Brisbin has verified the data disclosed herein. Data verification procedures included comparing radioactivity measured on core with the RS-125 spectrometer to radioactivity measured downhole with the 2PGA probe, comparing RS-125 data to cps values marked on core boxes in core photos, and checking reported composite lengths and cps values. For additional information regarding the Company’s Larocque East Project, including the current mineral resource estimate for IsoEnergy’s Hurricane Deposit, please see the technical report entitled “Technical Report on the Larocque East Project, Northern Saskatchewan, Canada” dated August 4, 2022, available on the Company’s profile at www.sedarplus.ca.

About IsoEnergy Ltd.

IsoEnergy (NYSE American: ISOU; TSX: ISO) is a leading, globally diversified uranium company with substantial current and historical mineral resources in top uranium mining jurisdictions of Canada, the U.S. and Australia at varying stages of development, providing near-, medium- and long-term leverage to rising uranium prices. IsoEnergy is currently advancing its Larocque East project in Canada’s Athabasca basin, which is home to the Hurricane deposit, boasting the world’s highest-grade indicated uranium mineral resource.

X: @IsoEnergyLtd www.isoenergy.ca

Cautionary Statement Regarding Forward-Looking Information

This press release contains forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation (collectively, referred to as “forward-looking information”). Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These forward-looking statements or information may relate to statements with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, including, without limitation, the anticipated results from the 2026 exploration activities and expected timing for reporting thereof. Generally, but not always, forward-looking information and statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof.

Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management at the time, are inherently subject to business, market and economic risks, uncertainties
and
contingencies
that
may
cause
actual
results,
performance
or
achievements
to
be
materially different from those expressed or implied by forward-looking statements. Such assumptions include, but are not
limited
to,
assumptions
that
the
results
of
planned
exploration
activities
are
as
anticipated;
the
anticipated mineralization
of
IsoEnergy’s
projects
being
consistent
with
expectations
and
the
potential
benefits
from
such projects and any upside from such projects; the price of uranium; that general business and economic conditions
will
not
change
in
a
materially
adverse
manner;
that
financing
will
be
available
if
and
when
needed and on reasonable terms; that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Company’s planned activities will be available on reasonable terms and in a timely manner. Although IsoEnergy has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking
information.

Such statements represent the current views of IsoEnergy with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by IsoEnergy, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Risks and uncertainties include, but are not limited to the following: negative operating cash flow
and
dependence
on
third
party
financing;
uncertainty
of
additional
financing;
no
known
mineral
reserves; aboriginal title and consultation issues; reliance on key management and other personnel; actual results of exploration activities being different than anticipated; changes in exploration programs based upon results; availability of third party contractors; availability of equipment and supplies; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena; other environmental risks; changes in laws and regulations; regulatory determinations and delays; stock market conditions generally; demand, supply and pricing for uranium; other risks associated with the mineral exploration industry, and general economic and political conditions in Canada, the United States and other jurisdictions where the Company
conducts
business.
Other
factors
which
could
materially
affect
such
forward-looking
information
are described in the risk factors in IsoEnergy’s most recent annual management’s discussion and analysis and annual
information
form
and
IsoEnergy’s
other
filings
with
the
securities
regulators
which
are
available
under the Company’s profile on SEDAR+ at

www.sedarplus.ca

and and on EDGAR at

www.sec.gov.

IsoEnergy does not undertake to update any forward-looking information, except in accordance with applicable securities
laws.


Cautionary Note to United States Investors Regarding Presentation of Mineral Resource Estimates

The mineral resource estimates included in this press release have been prepared in accordance with the requirements of the securities laws in effect in Canada and Australia, as applicable, which differ in certain material respects from the disclosure requirements promulgated by the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, information contained in this press release may not be comparable to similar information made public by U.S. companies reporting pursuant to SEC disclosure requirements.

IsoEnergy Ltd.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/isoenergy-completes-summer-drilling-at-larocque-east-intersecting-widespread-and-strongest-radioactivity-to-date-along-the-hurricane-south-trend-302871790.html

SOURCE IsoEnergy Ltd.

CIOs Carry the Blame for AI Failure, Often Without the Authority to Prevent It, 8×8 Survey Finds

CIOs Carry the Blame for AI Failure, Often Without the Authority to Prevent It, 8×8 Survey Finds

Technology leaders worldwide are struggling with an accountability gap between AI adoption and governance infrastructure

CAMPBELL, Calif.–(BUSINESS WIRE)–A majority of technology leaders, 52%, say they hold the CIO accountable when an AI agent makes an error. In fact, CIOs shoulder the blame far more often than any other function, including legal, compliance, and customer service.

That’s a topline finding of Communications Reckoning: When the AI Agent Fails, Someone Has to Answer, a global survey commissioned by 8×8, Inc. (NASDAQ: EGHT), a leading global business communications platform provider. In July 2026, 8×8 commissioned independent research through Censuswide, surveying 2,501 CIOs and CTOs across the UK, USA, France, Australia, and the Republic of Ireland to ask them what AI disruption looks like from the front lines.

“The CIO is now the last line of defense for AI, and in a lot of organizations, that’s a job they didn’t apply for,” said Samuel Wilson, Chief Executive Officer at 8×8, Inc. “The CIO didn’t choose the vendor and they don’t always have the audit trail. But when an AI agent gets it wrong, their name is the one in the incident report. That’s not sustainable, and it’s not how you build a governance model that holds up under scrutiny. The fix isn’t more oversight. It’s giving the people with the accountability the visibility to match it. ”

Fair or not, the CIO owns AI risk

Accountability for AI behavior across the business has landed on one desk, the CIO’s, and it has often happened without a matching increase in governance tools or authority. 52% of those surveyed said the CIO is on the hook when an AI agent makes an error, compared with just 16% for customer service leadership and 6% for legal or compliance teams.

Data sovereignty is now a board-level concern

The survey shows that 82% of responding CIOs say AI infrastructure location matters, with 30% calling it the primary factor in vendor decisions, and 52% describing it as one of several critical considerations. This reinforces data released last month showing 89% of technology leaders say data sovereignty has climbed their list of priorities over the past 12 months, reflecting mounting regulatory pressure tied to GDPR, HIPAA, CCPA, and similar regulations.

“While many think it’s only Europeans worrying about data sovereignty, the data shows that it’s a huge issue in the US as well,” said Wilson. “This reflects that when you are dealing with data jumping over borders and where infrastructure is located across multiple vendors and tech stacks, it’s really a problem for everyone.”

Consolidation has stalled, but not for lack of capable technology

When asked about streamlining vendors and their technology stack, only 9% of CIOs say no single platform can meet their organization’s requirements, a signal that the market has the technical capability to solve fragmentation. The largest obstacles were cited as being:

  • 30% said migration cost and complexity
  • 24% said regulatory or data residency constraints
  • 16% said vendor lock-in
  • 15% said internal politics and stakeholder alignment across teams

“The encouraging part of this research is that the technology to fix this fragmentation already exists,” Wilson added. “What’s missing is a partner willing to help organizations navigate the politics and the change management, not just sell them another platform. That’s the harder job, and for a partner willing to step up, there are rewards to be had.”

Governance is the biggest gap

Communications infrastructure is no longer only the supporting layer for AI. For most organizations, it has become the governance layer, the place where accountability, data control, and vendor sprawl all converge.

“CIOs aren’t short on technology options,” said Wilson. “They’re short on one view across everything they’ve already bought. Closing that gap is what will separate the organizations that get ahead with AI from the ones that just get exposed by it.”

The report, ‘Communications Reckoning: AI Complexity and the Multi-Vendor Data Problem,’ is available for download at https://www.8×8.com/communications-reckoning/when-ai-fails.

This is the first of a three-part Communications Reckoning series that will continue throughout 2026 and 2027.

About 8×8, Inc.

8×8, Inc. (NASDAQ: EGHT) connects people and organizations through seamless communication on one of the industry’s most integrated platforms for Customer Experience – combining Contact Center, Unified Communications, and CPaaS APIs. The 8×8® Platform for CX integrates AI to enable personalized customer journeys, drive operational excellence and insights, and facilitate team collaboration. As a business communications leader, the company helps customer experience and IT leaders around the world become the heartbeat of their organizations, empowering them to unlock the potential of every interaction. For additional information, visit www.8×8.com, or follow 8×8 on LinkedIn, X, and Facebook.

Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the expected impact of AI in the workplace and how businesses may respond. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied. For a more complete description of these and other risk factors, please refer to 8×8’s filings with the Securities and Exchange Commission. 8×8 undertakes no obligation to update these statements to reflect events occurring after the date of this press release, except as required by law.

8×8, Inc. Contacts:
Media:
PR@8×8.com

Investor Relations:
Investor.Relations@8×8.com

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: VoIP Technology Telecommunications Artificial Intelligence Software

MEDIA:

Logo
Logo

EQPT Investors Have Opportunity to Lead EquipmentShare.com Inc. Securities Fraud Lawsuit with SBS Law

PR Newswire

LOS ANGELES, Sept. 8, 2026 /PRNewswire/ — Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against EquipmentShare.com Inc. (“EquipmentShare” or “the Company”) (NASDAQ: EQPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of EQPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: January 23, 2026 to June 23, 2026

DEADLINE: September 21, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. EquipmentShare engaged in related party transactions that it failed to disclose. The Company did not end or even substantially reduce the number of transactions it completed with entities owned by its cofounders. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about EquipmentShare, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/eqpt-investors-have-opportunity-to-lead-equipmentsharecom-inc-securities-fraud-lawsuit-with-sbs-law-302871817.html

SOURCE Schall, Brown & Schwartz LLP

CCOI Investors Have Opportunity to Lead Cogent Communications Holdings, Inc. Securities Fraud Lawsuit with SBS Law

PR Newswire

LOS ANGELES, Sept. 8, 2026 /PRNewswire/ — Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cogent Communications Holdings, Inc. (“Cogent” or “the Company”) (NASDAQ: CCOI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of CCOI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: February 29, 2024 to May 1, 2026

DEADLINE: September 21, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Cogent’s backlog of supposed orders for its optical wavelength products were not likely to generate revenue. Customers in the Company’s backlog were unwilling to accept delivery even if it was capable of delivering its products and services. The Company was not on track to achieve revenue targets and other performance goals. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Cogent, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/ccoi-investors-have-opportunity-to-lead-cogent-communications-holdings-inc-securities-fraud-lawsuit-with-sbs-law-302871813.html

SOURCE Schall, Brown & Schwartz LLP

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma –

– Verekitug also delivered clinically meaningful improvements in lung function (FEV

1

) and exhaled nitric oxide (FeNO) with every 12-week dosing

– The Company remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in
Q1 2027
, designed to deliver best-in-class efficacy in both indications by evaluating a 400 mg quarterly regimen of verekitug in broad patient populations –

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for severe inflammatory respiratory diseases, today presented results from the Phase 2 VALIANT clinical trial evaluating the safety and efficacy of verekitug in adults with severe asthma in a late-breaking oral presentation at the European Respiratory Society (ERS) Congress 2026 in Barcelona. Verekitug is the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor.

As previously reported, VALIANT met the study’s primary endpoint of a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER) across all dose regimens studied. Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% (p<0.001) compared to placebo. Statistically significant reductions in AAER were also observed in the two other dose arms.

“We are excited to share results of the Phase 2 VALIANT study, which demonstrate that treatment with verekitug led to significant and substantial improvements in asthma exacerbations, lung function and inflammatory biomarkers, at this year’s ERS Congress,” said Aaron Deykin, MD, Chief Medical Officer and Head of Research & Development at Upstream Bio. “The compelling efficacy profile, highlighted by a 56% reduction in AAER observed in patients receiving verekitug every 12 weeks, together with the favorable safety results, reinforces the potential of targeting the TSLP receptor to potently address key measures of disease. These findings, part of the dataset from more than 500 trial participants treated with verekitug to date, further strengthen our conviction in verekitug’s potential to deliver best-in-class efficacy with the convenience of quarterly dosing, a profile we plan to further evaluate in a broad severe asthma population in Phase 3.”

“Despite the availability of effective biologic therapies, there continues to be a need for treatments that can provide meaningful disease control while reducing patient burden,” said Michael Wechsler, MD, MMSc, Professor of Medicine, Director of National Jewish Cohen Family Asthma Institute and principal investigator on the VALIANT trial. “The consistency and magnitude of improvement observed with verekitug in the VALIANT study suggests it has the potential to deliver meaningful clinical benefit for people living with severe asthma. The substantial reduction in asthma exacerbations, together with improvements across multiple measures of disease activity including lung function, demonstrate verekitug’s potential to achieve strong disease control with infrequent dosing. These results support its continued development as an important potential treatment option for severe asthma.”

VALIANT (NCT06196879) is a Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging, parallel group clinical trial that evaluated the safety and efficacy of verekitug in 478 patients with severe asthma. Patients were enrolled regardless of baseline blood eosinophil count or other type-2 biomarker levels. The trial was designed with a variable treatment period with all participants having at least 24 weeks of treatment and those enrolled prior to the last randomized participant having additional treatment up to a maximum of 60 weeks.

Verekitug improved the key secondary outcomes of FEV1 (forced expiratory volume in one second), FeNO (fractional exhaled nitric oxide), and asthma symptom control as measured by Asthma Control Questionnaire (ACQ-6) versus placebo at week 24, with improvements seen as early as week 2 across all key secondary outcomes.

Verekitug was generally well tolerated across all active doses, demonstrating a favorable safety profile consistent with previous studies. Immunogenicity had no meaningful impact on safety or efficacy results.

Eligible participants who completed the Phase 2 VALIANT clinical trial were offered enrollment in VALOUR (NCT06966479), a long-term extension (LTE) study designed to evaluate the long-term safety and efficacy of verekitug. VALOUR completed enrollment in March 2026 with more than 90% retention of eligible patients from the Phase 2 VALIANT study, with data expected in the second half of 2027.

As previously announced, Upstream Bio remains on track to initiate Phase 3 clinical trials with verekitug administered every 12 weeks in severe asthma and CRSwNP in the first quarter of 2027. The Phase 3 trials will evaluate 400 mg of verekitug administered every 12 weeks, versus placebo, with the goal to deliver best-in-class efficacy with quarterly at-home administration for patients with severe asthma and CRSwNP, in broad study populations without restriction based on baseline biomarkers.

A digital version of the presentation and e-poster can be found on the Publications section of the Upstream Bio website.

About Verekitug

Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody that binds to the thymic stromal lymphopoietin (TSLP) receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only known antagonist currently in clinical development that targets and inhibits the TSLP receptor.

TSLP is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy. TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases.

With more than 500 participants treated with verekitug across its clinical development programs and positive Phase 2 results in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), verekitug has a substantial body of clinical evidence supporting its advancement into Phase 3 development in both diseases. Verekitug is also being evaluated in an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD).

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company developing treatments for severe inflammatory respiratory diseases. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple inflammatory pathways. With more than 500 participants treated with verekitug across its clinical development programs and positive Phase 2 results in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, verekitug has a substantial body of clinical evidence supporting its advancement into Phase 3 development in both diseases. Verekitug is also being evaluated in an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD). Upstream Bio is focused on leveraging verekitug’s differentiated mechanism, potency, and potential for extended dosing to develop a treatment which may deliver best-in-class efficacy and quarterly dosing for patients underserved by today’s standard of care.

To learn more, please visit www.upstreambio.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “predict,” “project,” “seeks,” “should,” “target,” “will” and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: the clinical development of verekitug for the treatment of severe asthma, CRSwNP and COPD, including the Company’s plans to initiate Phase 3 clinical trials in severe asthma and CRSwNP in the first quarter of 2027 and the timing, progress and results of ongoing and planned clinical trials; expectations regarding the potential of verekitug to deliver best-in-class efficacy and its differentiation, safety, and tolerability; and expectations regarding regulatory interactions with the U.S. Food and Drug Administration, including the Company’s Phase 3 clinical development plans in severe asthma and CRSwNP and the outcomes of any such interactions. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream Bio’s ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the initiation, timing, progress and results of clinical trials; Upstream Bio’s ability to fund its development activities and achieve development goals; Upstream Bio’s dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream Bio’s ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream Bio’s financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities, including any additional interactions with the FDA regarding the sufficiency of Upstream Bio’s Phase 3 development plans; Upstream Bio’s competitors and industry; and other risks and uncertainties described in greater detail under the caption “Risk Factors” in Upstream Bio’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Upstream Bio’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Investor and Media Contact:

Meggan Buckwell
Senior Director, Corporate Communications and Investor Relations
[email protected]



DVLT Investors Have Opportunity to Lead Datavault AI Inc. Securities Fraud Lawsuit with SBS Law

PR Newswire

LOS ANGELES, Sept. 8, 2026 /PRNewswire/ — Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Datavault AI Inc. (“Datavault” or “the Company”) (NASDAQ: DVLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of DVLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: September 4, 2024 to October 30, 2025

DEADLINE: October 5, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Datavault overstated the value its AI brought to corporate partnerships with companies including Nature’s Miracle. The Company misled investors about the actual volume of trading activity on its platform. The Company suffered reputational harm when its ties to a convicted felon were revealed. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Datavault, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.             

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/dvlt-investors-have-opportunity-to-lead-datavault-ai-inc-securities-fraud-lawsuit-with-sbs-law-302871818.html

SOURCE Schall, Brown & Schwartz LLP

Brightstar Lottery PLC Announces Tender Offer and a Benchmark Offering of Senior Secured Notes Due 2032

PR Newswire

LONDON, Sept. 8, 2026 /PRNewswire/ — Brightstar Lottery PLC (NYSE: BRSL) (“Brightstar“) announced a tender offer (the “Offer“) for any and all of the Regulation S interests in its outstanding €500,000,000 2.375% Senior Secured Notes due 2028 (the “Notes“) on the terms and subject to the conditions set out in a tender offer memorandum dated as of today’s date (the “Tender Offer Memorandum“), and subject to the offer and distribution restrictions as set out in the Tender Offer Memorandum. Copies of the Tender Offer Memorandum are available, subject to registration and eligibility confirmation, at the following web address: https://deals.is.kroll.com/brightstar. Capitalized terms used herein but not defined have the meanings given to them in the Tender Offer Memorandum.

Brightstar Lottery

Brightstar also announced a benchmark offering (the “Offering“) of euro-denominated senior secured notes due 2032 (the “New Notes“). The New Notes will be guaranteed on a senior basis by certain of Brightstar’s wholly‑owned subsidiaries. Application has been made for the New Notes to be listed on the Official List of Euronext Dublin and admitted to trading on the Global Exchange Market of Euronext Dublin. Brightstar intends to use the gross proceeds from the sale of the New Notes (i) to pay the purchase price for the Regulation S interests in the Notes tendered and accepted for purchase in connection with the Offer and accrued and unpaid interest thereon, (ii) to repay utilizations under its senior revolving credit facilities and (iii) to pay fees and expenses incurred in connection with the Offer and the Offering.

The purpose of the Offer and the Offering is to extend the weighted average maturity of Brightstar’s debt. The completion of the Offering is a condition to the Offer (though such condition may be waived by Brightstar in its sole and absolute discretion).


Description of
the Notes


Outstanding
Principal
Amount


(1)


ISIN/Common
Code


Maturity Date


Purchase Price
per €1,000
Principal Amount
(the
Purchase
Price
)(2)


Amount Subject
to the Offer

€500,000,000
2.375% Senior
Secured Notes
due 2028

€500,000,000

XS2051904733/

205190473

April 15, 2028

€990.00

Any and all of the
Regulation S
interests in the
Notes

_________


(1)

The Outstanding Principal Amount comprises notes which were originally sold pursuant to Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act“) (ISIN/Common Code: XS2051904733/205190473), and notes originally sold pursuant to Rule 144A under the Securities Act (ISIN/Common Code: XS2051911605/205191160). For the avoidance of doubt, the Offer (as defined below) is only being made with respect to the notes held pursuant to Regulation S under the Securities Act (ISIN/Common Code: XS2051904733/205190473).


(2)

The Purchase Price is applicable only to Notes that are validly tendered and accepted pursuant to the Offer. In addition to the Purchase Price, Holders whose tender of the Notes is accepted and purchased pursuant to the Offer will also be paid a cash amount in euros equal to the accrued and unpaid interest on the Notes from and including the immediately preceding interest payment date up to, but excluding, the Settlement Date (as defined below). The Purchase Price and any accrued and unpaid interest will be payable on the Settlement Date.

Key Terms of the Invitation

Subject to the right of Brightstar to extend, terminate, re-open or amend the Offer, Brightstar will purchase for cash the Notes validly tendered by Holders and accepted by Brightstar. Notwithstanding any other provision of the Offer, Brightstar’s obligation to accept for purchase and to pay for the Notes validly tendered pursuant to the Offer is subject to, and conditioned upon, the satisfaction of or, where applicable, its waiver of the General Conditions and the Financing Condition. Brightstar is under no obligation to accept any tender of Notes for purchase pursuant to the Offer. Prior to acceptance for purchase by Brightstar of Notes pursuant to the Offer, Brightstar reserves the right, in its sole and absolute discretion, to reject tenders of Notes for any reason and Brightstar is under no obligation to Holders to furnish any reason or justification for refusing to accept a tender of Notes for purchase.

Purchase Price and Accrued Interest

The price Brightstar will pay for Notes tendered prior to the Tender Deadline and accepted for purchase pursuant to the Offer will be €990.00 per €1,000 (the “Purchase Price“).

All Holders of purchased Notes will receive, as well as the Purchase Price, a cash amount in euros equal to the accrued and unpaid interest on the Notes, from, and including, the immediately preceding interest payment date up to, but excluding, the applicable settlement date for Notes validly tendered, and which, subject to satisfaction or waiver of the conditions set forth in the Tender Offer Memorandum is expected to occur on the Settlement Date (as defined below) (such cash amount, “Accrued Interest“). For the avoidance of doubt, Accrued Interest will cease to accrue on the Settlement Date for all Notes accepted for purchase pursuant to the Offer.

New Notes and Financing Condition

On or prior to the Settlement Date, Brightstar expects to issue the New Notes on terms and conditions satisfactory to Brightstar in its sole and absolute discretion (the “Financing Condition“). Brightstar expects to pay the Purchase Price and Accrued Interest with proceeds from the issuance of the New Notes and, if necessary, cash on hand. The Offer is subject to the satisfaction of the Financing Condition. Brightstar may waive the Financing Condition in its sole and absolute discretion.

Priority Allocation of the New Notes

Brightstar will, in connection with allocations of the New Notes, consider, among other factors, the aggregate nominal amount of Notes tendered or firmly intended to be tendered by a Holder requesting an allocation of New Notes. Brightstar intends to give preference to such Holders (“New Issue Priority“). Any such preference will be in the sole and absolute discretion of Brightstar but will not exceed the aggregate nominal amount of Notes validly tendered or firmly indicated to be validly tendered pursuant to the Offer.

Brightstar is not obligated to allocate the New Notes to a Holder who has validly tendered or indicated a firm intention to validly tender the Notes pursuant to the Offer and, if any such New Notes are allocated, the nominal amount thereof may be less or more than the nominal amount of Notes tendered by such Holder and accepted for purchase by Brightstar pursuant to the Offer.

Any such allocation will also, among other factors, take into account the minimum denomination of the New Notes (being €100,000). Any allocation of the New Notes will be made in accordance with customary new issuance allocation processes and procedures.

In the event that a Holder validly tenders Notes pursuant to the Offer, such Notes will remain subject to such tender and the conditions of the Offer as set out in the Tender Offer Memorandum irrespective of whether such Holder receives all, some or none of the allocation of New Notes requested.

Holders should note that the pricing and allocation of the New Notes are expected to take place prior to the Tender Deadline and any Holder requesting an allocation of New Notes in addition to tendering Notes for purchase pursuant to the Offer should therefore provide as soon as practicable to any Joint Lead Dealer Manager an indication of a firm intention to tender Notes for purchase pursuant to the Offer and the aggregate nominal amount of Notes that such Holder intends to tender.

To request New Issue Priority, a Holder should contact a Joint Lead Dealer Manager in its capacity as manager for the New Notes as soon as possible using the contact details below. It is the sole responsibility of each Holder to satisfy itself that it is eligible to purchase New Notes before requesting priority in the allocation of the New Notes.

Electronic Instructions

To participate in the Offer, Holders of the Notes held through the Clearing Systems, must deliver, or arrange to have delivered on their behalf, through such Clearing System, and in accordance with the requirements of such Clearing System, by the relevant deadline, valid Electronic Instructions (as defined in the Tender Offer Memorandum) to Kroll Issuer Services Limited (the “Tender and Information Agent“) through such Clearing System and in accordance with the requirements of such Clearing System at or prior to the Tender Deadline, unless the Offer is extended, re-opened or terminated as provided in the Tender Offer Memorandum.

The submission of a valid Electronic Instruction in accordance with the procedures set out in the Tender Offer Memorandum will be irrevocable except in the limited circumstances described in the Tender Offer Memorandum, or as required by any applicable law. No acknowledgement of receipt of any Electronic Instruction or other documents will be given by the Issuer, the Dealer Manager or the Tender and Information Agent.

Brightstar will accept Notes for purchase only in minimum denominations of €100,000 and integral multiples of €1,000 in excess thereof. Holders who tender less than all of their Notes must continue to hold Notes in the minimum denomination of €100,000.

No alternative, conditional or contingent tenders will be accepted.

Expected Timetable of Events


Event


Indicative Date and Time


Description of Event

Launch Date

September 8, 2026.

Invitation to tender announced by Brightstar and Tender Offer Memorandum available from the Tender and Information Agent.

Tender Deadline

4:00 P.M. (London time) on
September 15, 2026.

The final deadline for receipt of valid Electronic Instructions by the Tender and Information Agent for Holders to participate in the Offer and to be eligible to receive the Purchase Price and Accrued Interest.

The deadline set by each Clearing System for the submission of Electronic Instructions will be earlier than the Tender Deadline.

Announcement of
Results 

As soon as reasonably practicable
following the Tender Deadline

Announcement of the aggregate principal amount of Notes validly tendered by the Tender Deadline and the aggregate principal amount of Notes to be accepted for purchase (subject to satisfaction of the General Conditions and the Financing Condition).

Settlement Date

The Settlement Date is expected to
be September 18, 2026.

Brightstar will deposit with the applicable Clearing System the amount of cash necessary to pay, and the applicable Clearing System, will pay, to each Holder whose Notes are accepted for purchase the Purchase Price and Accrued Interest.

Brightstar shall have no obligation to make or pay interest by reason of any delay by a Clearing System in making payments to the Holders or otherwise.

The above dates and times are subject, where applicable, to the right of Brightstar to extend, terminate, re-open or amend the Offer. Beneficial owners are advised to check with any broker, dealer, bank, custodian, trust company, direct participant or other intermediary or nominee through which they hold Notes whether such institution would require receipt of instructions to participate in the Offer prior to the deadline specified above.

The deadline set by each Clearing System for the submission of Electronic Instructions will be earlier than the relevant deadlines above.

Further Information

The Offer is described in full in the Tender Offer Memorandum which is available from the Tender and Information Agent (as detailed below). Requests for information in relation to the procedures for participating in the Offer should be directed to the Tender and Information Agent:

Kroll Issuer Services Limited
The News Building
3 London Bridge Street
London SE1 9SG
United Kingdom
Telephone: +44 20 7704 0880
Attention: Scott Boswell
E-mail: [email protected]
Invitation Website: https://deals.is.kroll.com/brightstar

The Joint Lead Dealer Managers for the Offer are:


Deutsche Bank AG, London Branch

21 Moorfields

London EC2Y 9DB

United Kingdom

Telephone: +44 207 545 8011

Attention: Liability Management Group


‌     


Banco Santander, S.A.

Ciudad Grupo Santander,

Edificio Encinar, Avenida de Cantabria s/n

28660, Boadilla del Monte

Madrid, Spain

Email: [email protected]

Attention: Liability Management

The Co-Dealer Managers for the Offer are:


Crédit Agricole Corporate and Investment Bank

12 Place des États Unis

CS 70052 92547

Montrouge Cedex

France

Tel.: +44 207 214 5553

Email: [email protected] 

Attention: Liability Management


ING Bank N.V., London Branch

8-10 Moorgate

London EC2R 6DA

United Kingdom

Telephone: +44 20 7767 6784

Email: [email protected]

Attention: Liability Management Team

DISCLAIMER

No offer or invitation to acquire any securities is being made pursuant to this news release. Each holder of the Notes (a “Holder“) is recommended to seek immediately its own legal advice and financial advice, including tax advice, relating to the consequences resulting from the Offer from its broker, bank, solicitor, accountant or other independent financial, legal or other advisor. Any individual or company whose Notes are held on its behalf by a broker, dealer, bank, custodian, trust company, direct participant or other intermediary or nominee must contact such entity if it wishes to tender such Notes pursuant to the Offer. None of the Joint Lead Dealer Managers, the Tender and Information Agent or Brightstar makes any recommendation as to whether Holders should tender Regulation S interests in the Notes pursuant to the Offer.

New Notes

Any investment decision to purchase any New Notes should be made solely on the basis of the information contained in (i) the preliminary offering memorandum dated September 8, 2026 and (ii) the pricing supplement prepared in connection with the New Notes and no reliance is to be placed on any representations, warranties or other information.

The New Notes are not being, and will not be, offered or sold in the United States. Nothing in the Tender Offer Memorandum constitutes an offer to sell or the solicitation of an offer to buy the New Notes in the United States or any other jurisdiction. The New Notes may not be offered, sold or delivered in the United States absent registration under, or an exemption from the registration requirements of the Securities Act. The New Notes have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or delivered, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S under the Securities Act).

MiFID II product governance – The target market for the New Notes is eligible counterparties and professional clients only, each as defined in Directive 2014/65/EU (as amended, “MiFID II“).

The New Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of MiFID II; or (ii) a customer within the meaning of Directive (EU) 2016/97, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation“) for offering or selling the New Notes or otherwise making them available to retail investors in the European Economic Area has been prepared and therefore offering or selling the New Notes or otherwise making them available to any retail investor in the European Economic Area may be unlawful under the PRIIPs Regulation.

The New Notes are not intended to be offered, sold, distributed or otherwise made available to and should not be offered, sold, distributed or otherwise made available to, any retail investor in the United Kingdom. For these purposes, a retail investor means a person who is either one (or both) of the following: (i) not a professional client as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (“EUWA“); or (ii) not a “qualified investor” as defined in paragraph 15 of Schedule 1 of the Public Offers and Admissions to Trading Regulations 2024. Consequently, no disclosure document required by the FCA Product Disclosure Sourcebook (“DISC“) for offering, selling or distributing the New Notes or otherwise making them available to retail investors in the United Kingdom may be unlawful under DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024. References to Regulations or Directives include, in relation to the United Kingdom, those Regulations or Directives as they form part of United Kingdom domestic law by virtue of the EUWA or have been implemented in United Kingdom domestic law, as appropriate.

No action has been or will be taken in any jurisdiction in relation to the New Notes to permit a public offering of securities.

OFFER AND DISTRIBUTION RESTRICTIONS

Neither this news release nor the Tender Offer Memorandum constitutes an invitation to participate in the Offer in or from any jurisdiction in or from which, or to any person to or from whom, it is unlawful to make the Offer or solicitation under any applicable securities, blue sky or other laws. The distribution of this news release and the Tender Offer Memorandum in certain jurisdictions may be restricted by law. Persons into whose possession this news release or the Tender Offer Memorandum comes are required by Brightstar, the Joint Lead Dealer Managers and the Tender and Information Agent to inform themselves about, and to observe, any such restrictions.

United Kingdom

The communication of this news release, the Tender Offer Memorandum and any other documents or materials relating to the Offer is not being made, and such documents or materials have not been approved, by an authorized person for the purposes of Section 21 of the Financial Services and Markets Act 2000, as amended (the “FSMA“). Accordingly, such documents or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents or materials is exempt from the restriction on financial promotions under Section 21 of the FSMA on the basis that it is only directed at and may be communicated to (i) persons who have professional experience in matters relating to investments, being investment professionals as defined in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Financial Promotion Order“); (ii) persons who fall within Article 43(2) of the Financial Promotion Order; or (iii) any other persons to whom these documents or materials may lawfully be made under the Financial Promotion Order. Any investment or investment activity to which this news release or the Tender Offer Memorandum relates is available only to such persons or will be engaged only with such persons and other persons should not rely on it.

European Economic Area

In any European Economic Area Member State, each of this news release and the Tender Offer Memorandum is only addressed to and is only directed at qualified investors in that Member State within the meaning of Regulation (EU) 2017/1129 (as amended), together with any applicable implementing measures in any Member State.

Italy

None of the Offer, this news release, the Tender Offer Memorandum or any other document or materials relating to the Offer have been or will be submitted to the clearance procedures of the Commissione Nazionale per le Società e la Borsa (“CONSOB“) pursuant to Italian laws and regulations. The Offer is being carried out in Italy as an exempted offer pursuant to Article 101-bis, paragraph 3-bis of Legislative Decree No. 58 of February 24, 1998, as amended (the “Financial Services Act“) and Article 35-bis, paragraph 3 of CONSOB Regulation No. 11971 of 14 May 1999, as amended. Holders or beneficial owners of the Notes that are located in Italy can tender Notes for purchase pursuant to the Offer through authorized persons (such as investment firms, banks or financial intermediaries permitted to conduct such activities in the Republic of Italy in accordance with the Financial Services Act, CONSOB Regulation No. 20307 of February 15, 2018, as amended from time to time, and Legislative Decree No. 385 of September 1, 1993, as amended) and in compliance with applicable laws and regulations or with requirements imposed by CONSOB or any other Italian authority.

General

This news release does not constitute an offer to buy or the solicitation of an offer to sell securities in any jurisdiction in which such offer or solicitation would be unlawful. None of the New Notes (i) may be offered, sold or delivered in the United States absent registration under, or an exemption from the registration requirements of, the Securities Act or (ii) have been, or will be, registered under the Securities Act, or the securities laws of the United States or any state thereof or the applicable laws of any other jurisdiction. In those jurisdictions where the securities, blue sky or other laws require the Offer to be made by a licensed broker or dealer and any Joint Lead Dealer Manager or either of the Joint Lead Dealer Managers’ respective affiliates is such a licensed broker or dealer in any such jurisdiction, the Offer shall be deemed to be made by such Joint Lead Dealer Manager or affiliate, as the case may be, on behalf of Brightstar in such jurisdiction.

In addition to the representations referred to above with respect to the United States, each Holder participating in the Offer will also be deemed to give certain representations in respect of the other jurisdictions referred to above and generally as set out in the applicable Tender Offer Memorandum. Any tender of Notes for purchase pursuant to the Offer from a Holder that is unable to make these representations will not be accepted. Each of Brightstar, each Joint Lead Dealer Manager and the Tender and Information Agent reserves the right, in its sole and absolute discretion, to investigate, in relation to any tender of Notes for purchase pursuant to the Offer, whether any such representation given by a Holder is correct and, if such investigation is undertaken and as a result Brightstar determines (for any reason) that such representation is not correct, such tender shall not be accepted.

About Brightstar Lottery PLC

Brightstar Lottery PLC (NYSE:BRSL) is a global leader in lottery focused on innovation and forward-thinking strategies and solutions, building on our renowned expertise in delivering secure technology and producing reliable, comprehensive solutions for our customers. As a premier pure play global lottery company, our best-in-class lottery operations, retail and digital solutions, and award-winning lottery games enable our customers to achieve their goals, entertain players and distribute meaningful benefits to communities. Brightstar has a well-established local presence and is a trusted partner to governments and regulators around the world, creating value by adhering to the highest standards of service, integrity, and responsibility. Brightstar serves nearly 90 lottery customers and their players on six continents. It is the primary technology provider to 26 of the 46 lottery jurisdictions in the U.S. and eight of the world’s 10 largest lotteries with central systems. Brightstar has approximately 6,000 employees. For more information, please visit www.brightstarlottery.com.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements (including within the meaning of the Private Securities Litigation Reform Act of 1995) concerning Brightstar Lottery PLC and its consolidated subsidiaries (the “Company“) and other matters. All statements, other than statements of historical facts, included in this news release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “plan,” “could,” “would,” “should,” “shall,” “continue,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project” or the negative or other variations of them. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements represent management’s good faith expectations, projections, guidance or beliefs concerning future events, and it is possible that the results described in this news release will not be achieved. Specifically, the Company cannot assure you that the proposed transactions described above, including the successful completion of the Offer and the Offering or, in the case of the Offer, will be made on the terms the Company currently contemplates, if at all. Information concerning these risks and other factors can be found in the offering memorandum for the New Notes, the Tender Offer Memorandum and the documents filed or furnished by the Company from time to time with the SEC, including the Company’s latest annual report on Form 20-F, which are available on the SEC’s website at www.sec.gov and on the investor relations section of the Company’s website at www.brightstarlottery.com. Except as required under applicable law, the Company does not assume any obligation to update these forward-looking statements. You should carefully consider these factors and other risks and uncertainties that may affect the Company’s business. All forward-looking statements contained in this news release are qualified in their entirety by this cautionary statement. All subsequent written or oral forward-looking statements attributable to the Company, or persons acting on its behalf, are expressly qualified in their entirety by this cautionary statement.

Contact:
Mike DeAngelis, Corporate Communications, +1 (401) 392-1000,
[email protected]
Matteo Selva, Italian media inquiries, +39 366 6803635
James Hurley, Investor Relations, +1 (401) 392-7190

© 2026 Brightstar Lottery PLC

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/brightstar-lottery-plc-announces-tender-offer-and-a-benchmark-offering-of-senior-secured-notes-due-2032-302871995.html

SOURCE Brightstar Lottery PLC

Logitech Unveils MX Keypad for Developers: The Customizable Multi-App AI Control Center

Logitech Unveils MX Keypad for Developers: The Customizable Multi-App AI Control Center

Master your AI workflow, with instant access to agents and coding tools

  • Works Across Multiple AI Coding Tools and IDEs: Execute prompt macros, refactor code and launch commands across GitHub Copilot, Claude Code, VS Code and IntelliJ IDEA.
  • Uniquely Customizable: Any key can be configured to control one or multiple apps and agents, providing developers unlimited flexibility.
  • Built for Developers, by Developers: Shaped by the GitHub and Logitech MX Collective communities’ feedback.

SAN JOSE, Calif. & LAUSANNE, Switzerland–(BUSINESS WIRE)–
Logitech (SIX: LOGN) (NASDAQ: LOGI) today announced MX Keypad, the AI control center designed for multi-app, multi-agent coding to put developers in command of their evolving workflows.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908069585/en/

Logitech unveils the MX Keypad for developers, a customizable multi-app AI control center designed to help you master your AI workflow with instant access to agents and coding tools.

Logitech unveils the MX Keypad for developers, a customizable multi-app AI control center designed to help you master your AI workflow with instant access to agents and coding tools.

Unlike other solutions on the market, MX Keypad offers cross-app compatibility with major coding platforms, allowing for unlimited customization tailored to each individual workflow. This unique level of versatility and personalisation allows coders to unify their AI workflows, complex prompts, and dev tools, for a continuous, uninterrupted flow across their entire stack. MX Keypad includes a selection of plugins, created and tested by developers, for GitHub Copilot and Claude Code.

“Today, coding mastery depends on how easily developers can juggle between an ever-increasing range of AI tools,” said Anatoliy Polyanker, VP and GM at Logitech. “MX Keypad puts a physical control center at your fingertips, allowing you to orchestrate your AI workflows faster and more intuitively.”

Microsoft GitHub Partnership

Developed in close collaboration with GitHub, MX Keypad will launch with native integration for GitHub including VS Code and the GitHub Copilot app, with ongoing plans to expand functionality across more tools over time. Every MX Keypad includes 3 free months of GitHub Copilot Pro+, redeemable in Logi Options+ for both new and existing users.

“Great developer tools get out of your way,” said Martin Woodward, VP of Developer Relations at GitHub. “MX Keypad makes working with GitHub Copilot feel like a natural part of the workflow, so developers can spend less time navigating tools and more time building.”

Built for Complete Personalization

The Logi Actions SDK, allows software engineers to build custom tools fast. With AI-friendly documentation, coding agents can generate custom integrations directly from the SDK, turning tasks into a simple afternoon project. The community has already published plugins for Claude Code and OpenAI Codex to the Logi Marketplace, giving developers real-time agent status tracking and CLI control right on the physical keys, reaching over 100 million compatible Logitech devices.

Designed for Sustainability

MX Keypad features certified post-consumer recycled plastic, 64% for graphite and 49% for pale grey colored models, and uses paper packaging from FSC™-certified forests and other controlled sources.

Pricing and Availability

MX Keypad will be available in select markets in Graphite and Pale Grey on September 8, 2026 for $99.99 USD/€99.99 on Logitech.com. For more information, visit www.logitech.com.

About Logitech

Logitech designs software-enabled hardware solutions that help businesses thrive and bring people together when working, creating and gaming. As the point of connection between people and the digital world, our mission is to extend human potential in work and play, in a way that is good for people and the planet. Founded in 1981, Logitech International is a Swiss public company listed on the SIX Swiss Exchange (LOGN) and on the Nasdaq Global Select Market (LOGI). Find Logitech and its other brands, including Logitech G, at www.logitech.com or company blog.

Logitech and other Logitech marks are trademarks or registered trademarks of Logitech Europe S.A. and/or its affiliates in the U.S. and other countries. All other trademarks are the property of their respective owners. For more information about Logitech and its products, visit the company’s website at www.logitech.com.

Wendy Spander

Logitech Global Communications

[email protected]

KEYWORDS: California Europe Switzerland United States North America

INDUSTRY KEYWORDS: Consumer Electronics Apps/Applications Technology Software Artificial Intelligence Hardware

MEDIA:

Photo
Photo
Logitech unveils the MX Keypad for developers, a customizable multi-app AI control center designed to help you master your AI workflow with instant access to agents and coding tools.
Logo
Logo

Magnite Launches First Agentic Campaign in EMEA With Amnet France

Results highlight the real-world impact of agentic buying for premium CTV campaigns

PARIS, Sept. 08, 2026 (GLOBE NEWSWIRE) — Magnite (NASDAQ:MGNI), the largest independent sell-side advertising company, today announced the launch of its first agentic campaign in EMEA in collaboration with the trading desk, Amnet France. The results offer a real-world look at the benefits agentic buying can have on improving the outcomes of premium CTV campaigns.

Using natural language prompts, Amnet leveraged Magnite’s buyer agent to build and activate a video campaign through ClearLine on behalf of a leading automotive manufacturer. Through Magnite Orchestration, the Magnite buyer agent communicated with the Magnite seller agent to identify and activate relevant premium CTV supply aligned with the campaign objectives, streamlining the path from buyer intent to execution. Rather than manually configuring campaign settings, identifying publishers and creating deal structures, the Amnet team was able to spend more time focused on strategy.

The results included an approximate 70% reduction in campaign setup time and a strong video view-through rate (VTR) of 95. The agent also surfaced relevant inventory and optimisation opportunities that may not have been identified through traditional manual workflows, helping teams make more informed campaign decisions.

Barbara Thuillier-Romeri, Ad-Tech Manager, Amnet France said: “As AI continues to mature, we wanted to understand how agentic technology could deliver practical value and complement the way we operate today. Working with Magnite gave us the opportunity to evaluate how their buyer agent could enhance the way our teams execute campaigns and drive stronger outcomes. We look forward to leveraging more of the product’s capabilities going forward, and are excited by the potential for this to evolve how we approach campaigns.”

“AI is only as valuable as the inventory and data it can access,” added Edouard Schmidt, Commercial Director, France at Magnite. “Because Magnite’s buyer agent is embedded directly into the buying workflow, it can surface optimisation opportunities as they emerge and allows buyers to act on them faster to improve both operational efficiency and campaign performance. The results achieved with Amnet reinforce the value of connecting intelligence directly to execution, and we’re excited to build on that momentum with more clients across EMEA.”

About Magnite

We’re Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising company. Publishers use our technology to monetize their content across all screens and formats including CTV, online video, display, and audio. The world’s leading agencies and brands trust our platform to access brand-safe, high-quality ad inventory and execute billions of advertising transactions each month. Anchored in bustling New York City, sunny Los Angeles, mile high Denver, historic London, colorful Singapore, and down under in Sydney, Magnite has offices across North America, EMEA, LATAM, and APAC.

About Amnet

Founded in 2012, Amnet France is a leading programmatic trading desk helping more than 200 advertisers in France and internationally, helping brands address a wide range of digital marketing challenges, from brand building and performance marketing to drive-to-store strategies, audience creation and data-driven targeting. Amnet delivers programmatic campaigns across all major digital channels, including Display, Video, Social, Audio, Connected TV (CTV), and Digital Out-of-Home (DOOH).

Media Contact:
Eric Van Damme: [email protected]